Oxaliplatin sensitizes OS Cells to TRAIL-induced apoptosis via down-regulation of Mcl1

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3477-3481

  Huang, Tao ^a   Gong, Wei Hua ^b   Li, Xiu Cheng ^a   Zou, Chun Ping ^a   Jiang, Guang Jian ^b   Li, Xu Hui ^b   Qian, Hao ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Osteosarcoma; Oxaliplatin; TRAIL

Indexed keywords

EID: 84873605983     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3477     Document Type: Article

References (28)

1. Arlt MJ, Walters DK, Banke IJ, et al (2011). The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. Int J Cancer, 131, E804-12.
2. Beaty O, 3rd Berg S, Blaney S, et al (2010). A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer, 55, 440-5.
3. Bouralexis S, Findlay DM, Atkins GJ, et al (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer, 89, 206-14.
4. Bruland OS, and Pihl A (1997). On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33, 1725-31.
5. Brunat-Mentigny, M., and Kohler, R. (1993). [Osteosarcoma]. Rev Prat, 43, 2197-203.
6. Clairambault J, Claude D, Filipski E, Granda T, Levi F (2003). [Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow osteosarcoma induced in mice: a mathematical model]. Pathol Biol (Paris), 51, 212-5.
7. El Fajoui Z, Toscano F, Jacquemin G et al (2011). Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology, 141, 663-73.
8. Geoerger B, Doz F, Gentet JC et al (2008). Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol, 26, 4394-400.
9. Gores GJ, Kaufmann SH (2012). Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev, 26, 305-11.
10. Hartmann C, Weinel P, Schmid H, et al (2011). Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. J Pediatr Hematol Oncol, 33, 344-349.
11. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA (2010). Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem, 285, 19162-72.
12. Kim J H, Park B, Gupta SC, et al (2012). Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid Redox Signal, 16, 413-27.
13. Kubista B, Erovic BM, Klinger H, Sulzbacher I, Trieb K (2004). CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett, 209, 105-10.
14. Lin F, Wang Q, Yu W et al (2011). Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol, 7, 270-5.
15. Locklin RM, Federici E, Espina B, et al (2007). Selective targeting of death receptor 5 circumvents resistance of MG- 63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther, 6, 3219-28.
16. Moon MH, Jeong JK, Seo JS, et al (2011). Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp Mol Med, 43, 138-145.
17. Pritchard DM, Berry D, Przemeck SM, et al (2008). Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol, 295, G798-805.
18. Rassidakis GZ, Lai R, McDonnell TJ, et al (2002). Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol 160, 2309-10.
19. Rizza SA, Challagundla KB, Natesampillai S, et al (2011). TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes. PLoS One, 6, e27171.
20. Seol DW (2011). p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun, 416, 222-5.
21. Song S, Choi K, Ryu, SW, Kang SW, Choi C (2011). TRAIL promotes caspase-dependent pro-inflammatory responses via PKCdelta activation by vascular smooth muscle cells. Cell Death Dis, 2, e223.
22. Takeda S, Iwai A, Nakashima M, et al (2007). LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. Anticancer Res, 27, 761-8.
23. Trieb K, Kotz R (2001). Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol, 33, 11-7.
24. Van Valen F, Fulda S, Schafer KL, et al (2003). Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer, 107, 929-40.
25. Wiley SR, Schooley K, Smolak PJ, et al (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-82.
26. Yuan JM, Li XD, Liu ZY, et al (2011). Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev, 12, 3465-9.
27. Zhang G, Li M, Jin J, Bai Y, Yang C (2011). Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev, 12, 2075-80.
28. Zhou W, Hu J, Tang H, et al (2011). Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors. BMC Cancer, 11, 485.